CYP2C8 and diabetes mellitus: Moreover, genetic polymorphisms in drug-metabolizing enzymes associated with diabetes—particularly mutations in CYP2C8—have been suggested to influence the metabolism of thiazolidinediones and bone metabolic pathways, potentially enhancing the individual susceptibility to medication-related osteonecrosis of the jaw [37].